EUVIMEDEUVIMED entdecken
Übersichtsarbeit

WEE-family kinases in cancer: synthetic lethal interactions and drug discovery

Chaofan Wang, Xiaoyun Lu

Trends in Pharmacological Sciences · 2026

DOI: 10.1016/j.tips.2025.09.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Trends in Pharmacological Sciences, 2026. Verfasst von Chaofan Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Moderni…. Hauptthemen laut MEDLINE: Protein-Tyrosine Kinases, Neoplasms, Cell Cycle Proteins, Protein Kinase Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 97 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Changjiang Scholar Program, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The WEE-family kinases, WEE1 and PKMYT1, play critical roles in regulating the G2/M cell cycle checkpoint to maintain genomic stability. Cancer cells with DNA damage response (DDR) deficiencies become heavily reliant on WEE1 and PKMYT1 to avert mitotic catastrophe. This dependence creates a synthetic lethality vulnerability that offers a promising therapeutic strategy. While early WEE1 inhibitors faced challenges due to toxicity, next-generation highly selective agents are now advancing through clinical trials with improved safety and efficacy. Similarly, PKMYT1 inhibitors have emerged as a complementary approach, with several candidates under clinical evaluation. This review examines the evolving mechanistic basis of synthetic lethality, with emphasis on how targeted inhibition of WEE1 or PKMYT1 exploits DDR defects to selectively induce genomic instability in cancer cells. Furthermore, we highlight recent advances in selective WEE kinase inhibitors, discuss key challenges, and explore innovative strategies to accelerate their development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Tyrosine KinasesNeoplasmsCell Cycle ProteinsProtein Kinase InhibitorsAntineoplastic AgentsProtein Serine-Threonine KinasesHumansDrug DiscoveryAnimalsDNA DamageMembrane Proteins

Stichwörter der Autor:innen

PKMYT1WEE1cancersynthetic lethality

Substanzen

Protein-Tyrosine KinasesWEE1 protein, humanCell Cycle ProteinsProtein Kinase InhibitorsAntineoplastic AgentsProtein Serine-Threonine KinasesPKMYT1 protein, humanMembrane Proteins

Autor:innen und Institutionen

  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Discovery of Chinese Ministry of Education,…

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province
  • Changjiang Scholar Program, Ministry of Education
  • National Key Research and Development Program of China

Zitieren

APA

Wang, C., & Lu, X. (2026). WEE-family kinases in cancer: synthetic lethal interactions and drug discovery. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2025.09.005

Vancouver

Wang C, Lu X. WEE-family kinases in cancer: synthetic lethal interactions and drug discovery. Trends in Pharmacological Sciences. 2026. doi:10.1016/j.tips.2025.09.005

BibTeX
@article{Wang2026,
  author = {Wang, Chaofan and Lu, Xiaoyun},
  title = {WEE-family kinases in cancer: synthetic lethal interactions and drug discovery},
  journal = {Trends in Pharmacological Sciences},
  year = {2026},
  doi = {10.1016/j.tips.2025.09.005}
}
Kostenlos starten →